HEMARINA, ORPHY, the UBO laboratory, and the University Hospital (CHRU) of Brest launch HEMOXYCHOC, the preclinic project designed to assess the efficacy & safety of HEMOXYCarrier® in the management of uncontrolled hemorrhagic shock.
Morlaix, February 11th, 2014 -
Hemorrhagic shock is the second leading cause of injury death after brain injuries. Such traumas lead to a reduction of patient oxygenation resulting from a... More +
For more information on HEMOXCell®, Cell growth activator, please refer to our brochure. More +
Technology & Products
News & Media
>> Company Overview >> Managment Team >> Board of Directors >> Scientific and Ethics Board >> Hemarina Label and Public Funding
>> Organ Preservation >> Wound Healing >> Hemoglobin Oxygen-Carrier >> Cell Culture and Bioproduction >> Other Perspective